Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: An Italian multicentric study and review of the literature

Autoimmunity Reviews

Volumn 11, Issue 11, 2012, Pages 815-820

  Bartoloni, Elena ^a   Alunno, Alessia ^a   Bistoni, Onelia ^a   Bizzaro, Nicola ^b   Migliorini, Paola ^c   Morozzi, Gabriella ^d   Doria, Andrea ^e   Mathieu, Alessandro ^f   Lotzniker, Milvia ^g   Allegri, Flavio ^h   Riccieri, Valeria ⁱ   Alpini, Claudia ^j   Gabrielli, Armando ^k   Tampoia, Marilina ^l   Gerli, Roberto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b S Antonio Hospital   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF CAGLIARI   (Italy)

^g AO Ospedale Civile   (Italy)

^h Ospedale Civile   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j UNIVERSITY OF PAVIA   (Italy)

^k UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^l POLICLINICO   (Italy)

more..

Author keywords

Anti mutated citrullinated vimentin antibodies; Anti viral citrullinated peptide 2 antibodies; Diagnostics; Rheumatoid arthritis

Indexed keywords

ANTIBODY; CITRULLINATED PEPTIDE 2 ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; MUTATED CITRULLINATED VIMENTIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SYNOVIUM;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PEPTIDES, CYCLIC; REPRODUCIBILITY OF RESULTS; ROC CURVE; VIMENTIN;

EID: 84865402057     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.02.015     Document Type: Review

References (37)

1. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O. Rheumatoid arthritis classification criteria. An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
2. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
3. van der Liden M.P., Knevel R., Huizinga T.W., van der Helm-van Mil A.H. Comparison of the 1987 American College of Rheumatology Criteria and the 2010 American College of Rheumatology/European League against Rheumatism Criteria. Arthritis Rheum 2011, 63:37-42.
4. Taylor P., Gartemann J., Hsieh J., Creeden J. A systematic review of serum biomarkers anti-cyclic citrullinated peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmun Dis 2011, 2011:815038.
5. Conrad K., Roggenbuck D., Reinhold D., Dörner T. Profiling of rheumatoid arthritis associated autoantibodies. Autoimmun Rev 2010, 9:431-435.
6. Wiik A.S., van Venrooij W.J., van Beers J., Pruijn G. All you wanted to know about anti-CCP but were afraid to ask. Autoimmun Rev 2010, 10:90-93.
7. Szodoray P., Szabó Z., Kapitány A., Gyetvai A., Lakos G., Szántó S., et al. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2010, 9:140-143.
8. Bizzaro N., Allegri F., Alpini C., Doria A., Gerli R., Lotzniker M., et al. Multicentric evaluation of a second assay to detect antiviral citrullinated peptide antibodies: a collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni. Clin Pathol 2011, 64:1139-1141.
9. Pratesi F., Tommasi C., Anzilotti C., Puxeddu I., Sardano E., Di Colo G., et al. Antibodies to a new viral citrullinated peptide, VCP2: fine specificity and correlation with anti-cyclic citrullinated peptide (CCP) and anti-VCP1 antibodies. Clin Exp Immunol 2011, 164:337-345.
10. Vossenaar E., Després N., Lapointe E., van der Heijden A., Lora M., Senshu T., et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004, 6:R142-R150.
11. Bang H., Egerer K., Gauliard A., et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007, 56:2503-2511.
12. Luime J.J., Colin E.M., Hazes J.M., Lubberts E. Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 2010, 69:337-344.
13. El-Barbary A., Kassem E., El-Sergany M., Essa S., Eltomey M. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide. J Rheumatol 2011, 38:828-834.
14. Gerli R., Bartoloni Bocci E., Sherer Y., Vaudo G., Moscatelli S., Shoenfeld Y. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:724-725.
15. Syversen S.W., Goll G.L., van der Heijde D., Landewé R., Lie B., Ødegård S., et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis 2010, 69:345-351.
16. Roland P., Mignot S., Bruns A., Hurtado M., Palazzo E., Hayem G., et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther 2008, 10:R142.
17. van der Linden M., van der Woude D., Ioan-Facsinay A., Levarht E.W., Stocken-Rijsbergen G., Huizinga T., et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009, 60:2232-2241.
18. Besada E., Nikolaisen C., Nossent H. Diagnostic value of antibodies against mutated citrullinated vimentin for rheumatoid arthritis. Clin Exp Rheumatol 2011, 29:85-88.
19. Innala L., Kokkonen H., Eriksson C., Jidell E., Berglin, Rantapää-Dahlqvist S. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008, 35:1002-1008.
20. Engelmann R., Brandt J., Eggert M., Karberg K., Krause A., Neeck G., et al. The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders. J Rheumatol 2009, 36:2670-2674.
21. Mathsson L., Mullazchi M., Wick M.C., Sjoberg O., van Vollenhoven R., Klareskog L. Antibodies against citrullinated vimentin in rheumatoid arthritis. Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008, 58:36-45.
22. Wagner E., Skoumal M., Bayer P., Klaushofer K. Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol Int 2009, 29:1315-1321.
23. Maraina C., Nurdayana A., Rusni D., Azwany Y. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis. Intern J Rheum Dis 2010, 13:335-339.
24. Sghiri R., Khalifa O., Bouajina E., Slama F., Baccouche K., Fredj H., et al. Presence and diagnostic performances of IgA class antibodies to mutated citrullinated vimentin in rheumatoid arthritis. Joint Bone Spine 2010, 77:277-280.
25. Ursum J., Nielen M.M., van Schaardenburg D., van der Horst A.R., van de Stadt R., Dijkmans B., et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 2008, 10:R12.
26. Liu X., Jia R., Zhao J., Li Z. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis. J Rheumatol 2009, 36:1136-1142.
27. Raza K., Mathsson L., Buckley C., Filer A., Rönnelid J. Anti-modified citrullinated vimentin (MCV) antibodies in patients with very early synovitis. Ann Rheum Dis 2010, 69:627-628.
28. Damjanovska L., Thabet M., Levarth E., Stoeken-Rijsbergen G., van der Voort E., Toes R., et al. Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 2010, 69:730-732.
29. Svård A., Kastbom A., Söderlin M., Reckner-Olsson A., Skogh T. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early rheumatoid arthritis. J Rheumatol 2011, 38:1265-1272.
30. Dejaco C., Klotz W., Larcher H., Duftner C., Schirmer M., Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R119.
31. Zehairy M., Soliman E., Daghaidy A. Antibodies to mutated citrullinated vimentin in patients with chronic hepatitis C virus genotype IV infection-related arthrtopathy. Rheumatol Int 2011, [Epub ahead of print].
32. Palazzi C., Buskila D., D'Angelo S., D'Amico E., Olivieri I. Autoantibodies in patients with chronic hepatitis C virus infection: pitfalls for the diagnosis of rheumatic diseases. Autoimmun Rev 2011, [Epub ahead of print].
33. Tsubota A., Matsumoto K., Mogushi K., Nariai K., Namiki Y., Hoshina S., et al. IQGAP1 and vimentin are key regulator genes in naturally occurring hepatotumorigenesis induced by oxidative stress. Carcinogenesis 2010, 31:504-511.
34. Meriden Z., Forde K.A., Pasha T., Hui J.J., Reddy K., Furth E., et al. Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 2010, 8:289-296.
35. Bizzaro N., Tonutti E., Tozzoli R., Villalta D. Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 2007, 53:1527-1533.
36. Meron M., Amital H., Shepshelovich D., Barzilai O., Ram M., Anaya J., et al. Infectious aspects and the etiopathogenesis of rheumatoid arthritis. Clin Rev Allerg Immunol 2010, 38:287-291.
37. Bossuyt X. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev 2009, 8:543-548.